Gliomyosarcoma: an immunohistochemical analysis

S R Stapleton, W Harkness, P R Wilkins, D Uttley

Abstract
Tumours of mixed glial and sarcomatous elements occurring in intracranial neoplasms are well recognised and have been termed gliosarcomas. These tumours account for up to 8% of all glioblastomas. The sarcomatous elements are thought to derive from the neoplastic transformation of mesenchymal cells adjacent to the tumour. This transformation usually has the appearance of a fibrosarcoma or angiosarcoma. Alternative mesenchymal neoplastic differentiation may occur, however, giving rise to the appearances of chondrosarcoma and osteosarcoma. In 1969 Goldman described a case in which the sarcomatous elements of a mixed gliosarcoma appeared, on the basis of light microscopy alone, to differentiate towards skeletal muscle having the features of a rhabdomyosarcoma. He coined the term gliomyosarcoma. In 1986 Barnard et al reported a second case and demonstrated the features of rhabdomyosarcoma using the electron microscope. A further case characterised with both light microscopic and immunohistochemical techniques is reported.

Histology
Paraffin wax sections showed a tumour with a biphasic pattern. Discrete islands of pleomorphic glial fibre producing tumour cells that stained positively for glial fibrillary acidic protein (GFAP) (fig 2a) and vimentin were surrounded by a spindle cell sarcomatous component that was rich in reticulin fibres and positive for vimentin but negative for GFAP. Within the sarcomatous element were elongated strap-like cells and rounded, intensely eosinophilic cells with the appearance of rhabdomyoblasts. Cross striations were readily identified (fig 2b). These cells were strongly positive for the markers desmin (fig 2c) and myoglobin (fig 2d) as well as vimentin. The appearances were those of a gliosarcoma showing rhabdomyoblastic differentiation.

Discussion
The term gliosarcoma was first used by Stroebel in 1895 to describe sarcomatous change in a glioblastoma. Since then the entity has been well described by Feigin et al and by Rubinstein. The tumour is said to account for 8% of all glioblastomas. Light microscopic and immunohistochemical exam-

Figure 1 Contrasted CT scan showing a moderately well demarcated enhancing mass in the left temporal lobe.
Gliomyosarcoma: an immunohistochemical analysis

*Figure 2.* Islands of glial fibrillary acidic protein (GFAP) positive tumour cells (arrows) amongst immunonegative sarcomatous tissue. (original objective magnification × 20); b Areas of rhabdomyoblastic differentiation with elongated cells showing cross-striations. (Haematoxylin and eosin, original objective magnification × 40); c Strap-like cells showing immunopositivity for desmin. (arrows) (original objective magnification × 20); d Strap-like cells showing immunopositivity for myoglobin. (arrows) (original objective magnification × 20).

Inclusions reveal prominent spindle cells with the nuclear features that suggest fibrosarcoma or angiosarcoma and may even show chondroid or osteoid metaplasia. In 1969 Goldman described a case of gliosarcoma with light microscopic evidence of rhabdomyoblastic differentiation and coined the term gliomyosarcoma. In 1971 a case of a mixed tumour containing both astrocytic and mesenchymal elements, with light microscopic features of rhabdomyoblasts was described by Shuangshui and Netsky.

In 1986 Barnard et al reported another case with electron microscopic features of striated muscle and recently rhabdomyoblastic differentiation has been described in a subependymoma. We have identified a case of gliosarcoma with rhabdomyoblastic differentiation using light microscopic and immunohistochemical techniques.

The occurrence of rhabdomyoblastic differentiation in various neuroepithelial tumours is well recognised as in the medulloblastoma and the medulloepithelioma of childhood, and is a feature of malignant schwannoma (malignant Triton tumour) and ganglioneuroma or malignant ectomesenchymoma. Primary cerebral rhabdomyosarcoma has also been described. An explanation for such divergent differentiation in these tumours may lie in the pleuripotential potency of the proposed cells of origin in the primitive medullary epithelium and hence their tendency to occur in childhood.

By contrast, the gliosarcoma is a tumour with an age distribution more akin to the purely glial tumours of the CNS. The debate on such tumours relates to the origin of the sarcomatous element. As in the childhood tumours, the gliosarcoma may represent one manifestation of a bimodal differentiation potential along neuroepithelial and mesenchymal lines. Rhabdomyoblastic cells would then be present as a result of an extension of the pleuripotential nature of these neoplastic mesenchymal cells. An alternative explanation is that the sarcomatous elements of the gliosarcoma arise by metaplasia of the connective tissue stroma and ultimately malignant transformation, possibly under the influence of transforming growth factors or oncogene activating factors elaborated by the malignant glial component; the process is termed "horizontal malignant transformation". In view of the age distribution of the cases described this latter mechanism seems the most plausible explanation for the gliosarcoma.

We have demonstrated the presence of rhabdomyoblasts within a gliosarcoma both under the light microscope and immunohistochemically, using the muscle cell markers desmin and myoglobin. The expanding use of such immunohistochemical markers will no doubt reveal that this type of cellular differentiation occurs more frequently than previously appreciated.

We thank Mrs G Thompson for preparation of the manuscript and Miss P Philpott for the photographs.

2 Goldman RL. Gliomyosarcoma of the cerebellum. Am J Clin


Gliomyosarcoma: an immunohistochemical analysis.

S R Stapleton, W Harkness, P R Wilkins and D Uttley

*J Neurol Neurosurg Psychiatry* 1992 55: 728-730
doi: 10.1136/jnnp.55.8.728

Updated information and services can be found at:
http://jnnp.bmj.com/content/55/8/728

**Email alerting service**

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/